We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. AbCellera Biologics Inc. (ABCL - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
AbCellera Biologics Inc. is one of 887 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AbCellera Biologics Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ABCL's full-year earnings has moved 7.4% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ABCL has gained about 39.5% so far this year. Meanwhile, the Medical sector has returned an average of -6.2% on a year-to-date basis. This shows that AbCellera Biologics Inc. is outperforming its peers so far this year.
Another stock in the Medical sector, Adlai Nortye Ltd. Sponsored ADR (ANL - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 881.7%.
The consensus estimate for Adlai Nortye Ltd. Sponsored ADR's current year EPS has increased 45.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, AbCellera Biologics Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 431 individual stocks and currently sits at #145 in the Zacks Industry Rank. Stocks in this group have gained about 1.2% so far this year, so ABCL is performing better this group in terms of year-to-date returns. Adlai Nortye Ltd. Sponsored ADR is also part of the same industry.
Investors with an interest in Medical stocks should continue to track AbCellera Biologics Inc. and Adlai Nortye Ltd. Sponsored ADR. These stocks will be looking to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. AbCellera Biologics Inc. (ABCL - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
AbCellera Biologics Inc. is one of 887 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AbCellera Biologics Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ABCL's full-year earnings has moved 7.4% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ABCL has gained about 39.5% so far this year. Meanwhile, the Medical sector has returned an average of -6.2% on a year-to-date basis. This shows that AbCellera Biologics Inc. is outperforming its peers so far this year.
Another stock in the Medical sector, Adlai Nortye Ltd. Sponsored ADR (ANL - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 881.7%.
The consensus estimate for Adlai Nortye Ltd. Sponsored ADR's current year EPS has increased 45.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, AbCellera Biologics Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 431 individual stocks and currently sits at #145 in the Zacks Industry Rank. Stocks in this group have gained about 1.2% so far this year, so ABCL is performing better this group in terms of year-to-date returns. Adlai Nortye Ltd. Sponsored ADR is also part of the same industry.
Investors with an interest in Medical stocks should continue to track AbCellera Biologics Inc. and Adlai Nortye Ltd. Sponsored ADR. These stocks will be looking to continue their solid performance.